Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3670553 | 0.98 | ACHE (0.70) | ACHENAAAEPHX1TSHRALDH1A1 | |
| SCHEMBL6577987 | 0.89 | ACHE (0.61) | ACHENAAAEPHX1TSHRALDH1A1 | |
| SCHEMBL28180783 | 0.85 | ACHE (0.61) | ACHENAAAEPHX1ALDH1A1TP53 | |
| SCHEMBL4555961 | 0.80 | NAAA (0.56) | ACHENAAAEPHX1TSHRALDH1A1 | |
| SCHEMBL28066180 | 0.79 | ACHE (0.57) | ACHENAAAEPHX1TSHRTP53 | |
| SCHEMBL4278518 | 0.79 | ACHE (0.57) | ACHENAAAEPHX1TP53RAD52 | |
| SCHEMBL9509262 | 0.79 | ACHE (0.54) | ACHENAAATSHRALDH1A1MAPK1 | |
| SCHEMBL11615274 | 0.79 | NAAA (0.50) | ACHENAAAEPHX1TSHRALDH1A1 | |
| SCHEMBL10812728 | 0.78 | NAAA (0.59) | ACHENAAAEPHX1TSHRALDH1A1 | |
| SCHEMBL11495665 | 0.78 | ACHE (0.54) | ACHENAAAEPHX1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194502-A1 | Protecting Groups for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | claimed |
| CN-117580847-A | Macrolide compounds | 范德比尔特大学 | 2024-02-20 | — | — | CN | disclosed |
| US-8242258-B2 | 2' protected nucleoside monomers protected with orthoester-type and acyl carbonate groups; solid phase synthesis of RNA, oxidation and deprotecting, removal from the support | AGILENT TECHNOLOGIES, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | HUANG TIEN L | 2010-10-21 | — | — | US | disclosed |
| US-20080194502-A1 | Protecting Groups for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008070831-A2 | BISBENZAMIDINES AND BISBENZAMIDOXIMES FOR THE TREATMENT OF HUMAN AFRICAN TRYPANOSOMIASIS | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | TOP2A, TOP2B, TOP1 | ACHE 408/4885NAAA 1268/4885EPHX1 4004/4885 |
| US-20080194502-A1 | Protecting Groups for RNA Synthesis | NSUN2, NSUN3, RNGTT | ACHE 4630/4885NAAA 1043/4885EPHX1 2699/4885 |
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | PBRM1, TFB2M, ABAT | ACHE 1688/4885NAAA 666/4885EPHX1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.